|Bid||0.00 x 12000|
|Ask||0.00 x 12000|
|Day's range||15.85 - 15.90|
|52-week range||15.31 - 49.99|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.80|
SOMERVILLE, Mass, August 04, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the second quarter ended June 30, 2022, and shared recent operational progress.
If you want to know who really controls bluebird bio, Inc. ( NASDAQ:BLUE ), then you'll have to look at the makeup of...
SOMERVILLE, Mass., June 10, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of betibeglogene autotemcel (beti-cel) for the treatment of people with beta-thalassemia who require regular red blood cell (RBC) transfusions.